BioHarvest Sciences, Inc. (BHST.CA) Stock Price, Financials & Summary

Key data

Open—

From 52W high—

Volume—

Market cap—

P/E (TTM)—

P/S (TTM)—

Div yield—

Key data

Open

—

From 52W high

—

Volume

—

Market cap

—

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

P/E (TTM)

—

RSI (14)

—

MomentumView details →

1D Return

—

YTD Return

—

SummaryUpdated Jun 1, 2026

BioHarvest Sciences Inc. (NASDAQ:BHST) is a Canadian biotechnology company founded to revolutionize how botanical compounds are produced for nutraceutical and pharmaceutical applications. Based in Vancouver, Canada, with operations in Israel and the United States, the company has developed a proprietary botanical synthesis platform that enables the cultivation of plant cells in bioreactors rather than traditional farming methods. Since completing its NASDAQ uplisting in 2024, BioHarvest has positioned itself as both a direct-to-consumer wellness brand and a contract development and manufacturing organization (CDMO) serving pharmaceutical and food industry clients.

Ask drillr about BioHarvest Sciences, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

—

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

—

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

—

ROA (TTM)

—

Asset Turnover

—

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

—

YTD Return

—

1Y Return

—

RSI (14)

—

vs 50D SMA

—

vs 200D SMA

—

Capital & dividendView details →

Debt/Equity

—

Current Ratio

—

Quick Ratio

—

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

35.48M

Net Income (TTM)

−11.07M

Op. CF (TTM)

−8.71M

Latest newsMore news →

Tate & Lyle Plc and BIOHARVEST SCIENCES INC. announced that their next-generation sweetener development programme demonstrated BioHarvest's Botanical Synthesis platform can produce the targeted sweetening solution.16d ago

Latest newsMore news →

BioHarvest Sciences said Olive Cell, an olive-derived plant-cell ingredient, is ready for commercial licensing after completing large-scale bioreactor scale-up, manufacturing readiness and a self-affirmed U.S. GRAS process.10d ago Tate & Lyle Plc and BIOHARVEST SCIENCES INC. announced that their next-generation sweetener development programme demonstrated BioHarvest's Botanical Synthesis platform can produce the targeted sweetening solution.16d ago